Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
PTC Therapeutics, Inc.'s quarterly P/E stands at 76.7x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 8.76 | 76.71 | — | 1.27 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.15 | 6.33 | 5.33 | 0.94 | 4.09 | 3.63 | 3.14 | 2.65 | 1.69 | 2.15 | 3.55 | 4.05 | 4.14 |
| — | +74.7% | +69.8% | -64.7% | +141.2% | +68.8% | -11.6% | -34.6% | -59.1% | -48.1% | -17.7% | -9.3% | -2.8% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | 1.27 | — | — | — | 86.79 | — | — | — | — | — |
| — | — | — | -98.5% | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 5.61 | 126.83 | — | 0.85 | — | — | — | 52.77 | 11.08 | — | — | — | — |
| — | — | — | -98.4% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 5.61 | 188.21 | — | 0.86 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
PTC Therapeutics, Inc.'s operating margin was 1.4% in Q3 2025, up 21.0 pp QoQ and up 29.1 pp YoY. The trailing four-quarter average of -2.9% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 52.3% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 45.1% | 93.6% | 98.9% | 92.4% | 94.5% | 91.7% | 93.0% | 65.4% | 95.2% | 94.0% | 93.6% | 93.5% |
| — | -52.3% | +2.1% | +6.4% | +41.3% | -0.7% | -2.5% | -0.6% | -30.1% | +1.7% | -0.1% | +0.4% | -0.9% | |
| Operating Margin | 50.1% | 1.4% | -19.5% | 82.5% | -76.2% | -27.7% | -21.5% | -21.6% | 1.0% | -60.1% | -98.0% | -53.4% | -119.7% |
| — | +105.2% | +9.3% | +481.4% | -7597.0% | +53.9% | +78.0% | +59.5% | +100.8% | -77.6% | -75.6% | +8.3% | -133.4% | |
| Net Margin | 39.4% | 7.5% | -36.3% | 73.7% | -30.9% | -54.2% | -53.1% | -43.6% | -50.7% | -67.6% | -93.0% | -63.1% | -102.1% |
| — | +113.9% | +31.8% | +269.1% | +39.1% | +19.9% | +42.9% | +30.9% | +50.3% | -34.4% | -1.2% | +26.0% | -17.7% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 29.7% | 0.6% | -2.5% | 39.7% | -3.7% | -5.7% | -5.4% | -5.0% | -9.9% | -10.2% | -13.5% | -8.4% | -10.4% |
| — | +110.6% | +54.2% | +899.8% | +62.4% | +44.6% | +60.3% | +40.7% | +5.2% | -58.3% | -59.9% | -23.7% | -43.4% | |
| ROIC | — | 0.5% | — | — | -20.5% | — | — | — | 0.7% | — | — | -19.4% | -32.7% |
| — | — | — | — | -3104.3% | — | — | — | +102.1% | — | — | -105.8% | -294.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
PTC Therapeutics, Inc.'s Debt/EBITDA ratio is 176.4x — elevated, raising questions about debt serviceability. The current ratio has improved 10.5% YoY to 2.32x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 0.46 | 176.43 | — | 0.40 | — | — | — | 42.39 | 26.59 | — | — | — | — |
| — | — | — | -99.1% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.35 | 2.32 | 3.62 | 3.89 | 2.35 | 2.10 | 2.23 | 2.03 | 2.02 | 1.10 | 1.24 | 1.39 | 1.71 |
| — | +10.5% | +62.6% | +91.3% | +16.3% | +91.1% | +79.9% | +46.5% | +18.3% | -10.8% | +1.1% | -14.4% | -8.9% | |
| Quick Ratio | 2.27 | 2.26 | 3.57 | 3.85 | 2.31 | 2.04 | 2.17 | 1.98 | 1.97 | 1.03 | 1.17 | 1.33 | 1.65 |
| — | +10.6% | +64.0% | +94.5% | +17.3% | +99.0% | +85.7% | +49.2% | +19.1% | -14.3% | -2.3% | -16.5% | -10.2% | |
| Interest Coverage | — | 0.09 | -1.15 | 28.46 | -3.95 | -1.31 | -0.92 | -1.11 | 0.07 | -4.20 | -7.12 | -4.30 | -8.18 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonPTC Therapeutics, Inc.'s current P/E is 8.8x. The average P/E over the last 2 quarters is 39.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
PTC Therapeutics, Inc.'s current operating margin is 50.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PTC Therapeutics, Inc.'s business trajectory between earnings reports.